SCHEMBL259052 — predicted protein targets

Predicted protein targets (top 12)

	gene	UniProt	supporting neighbours	confidence
▸	PSMB8	P28062	4/20	1.00

▸	RXFP1	Q9HBX9	2/20	1.00

▸	NPSR1	Q6W5P4	1/20	1.00

▸	ALDH1A1	P00352	5/20	0.63

▸	HPGD	P15428	3/20	0.63

▸	SMN1; SMN2	Q16637	2/20	0.58

▸	RAB9A	P51151	1/20	0.54

▸	APOBEC3G	Q9HC16	1/20	0.50

▸	MAPT	P10636	1/20	0.49

▸	MEN1	O00255	1/20	0.46

▸	KMT2A	Q03164	1/20	0.46

▸	KDM4E	B2RXH2	1/20	0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL13599975	0.78	ALDH1A1 (1.00)	PSMB8RXFP1NPSR1ALDH1A1HPGD
SCHEMBL104742	0.74	LMNA (0.63)	PSMB8RXFP1NPSR1ALDH1A1HPGD
SCHEMBL2496853	0.74	RXFP1 (0.59)	PSMB8RXFP1NPSR1ALDH1A1HPGD
SCHEMBL14542657	0.74	ALDH1A1 (1.00)	PSMB8RXFP1NPSR1ALDH1A1HPGD
SCHEMBL14516317	0.74	RXFP1 (0.58)	PSMB8RXFP1NPSR1ALDH1A1HPGD
SCHEMBL6299915	0.72	ALDH1A1 (0.70)	PSMB8RXFP1NPSR1ALDH1A1SMN1; SMN2
SCHEMBL25079381	0.72	PSMB8 (0.56)	PSMB8RXFP1NPSR1ALDH1A1HPGD
SCHEMBL22892410	0.72	PSMB8 (0.56)	PSMB8RXFP1NPSR1ALDH1A1HPGD
SCHEMBL17383212	0.72	RXFP1 (0.56)	PSMB8RXFP1NPSR1ALDH1A1HPGD
SCHEMBL19411179	0.71	ALDH1A1 (0.64)	PSMB8RXFP1NPSR1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-9669029-B2	Heteroaromatic phenylimidazole derivatives as PDE10A enzyme inhibitors	H. LUNDBECK A/S (DK)	2017-06-06	—	—	US	disclosed
US-9592230-B2	Substituted imidazoles as PDE10A inhibitors	H. LUNDBECK A/S (DK)	2017-03-14	—	—	US	disclosed
US-9592230-B2	Substituted imidazoles as PDE10A inhibitors	H. LUNDBECK A/S (DK)	2017-03-14	—	—	US	disclosed
US-20170001983-A1	TRPA1 MODULATORS	ALGOMEDIX, INC.	2017-01-05	—	—	US	disclosed
US-20150290191-A1	Heteroaromatic Phenylimidazole derivatives as PDE10A enzyme inhibitors	H. LUNDBECK A/S (DK)	2015-10-15	—	—	US	disclosed
US-9096589-B2	Heteroaromatic phenylimidazole derivatives as PDE10A enzyme inhibitors	H. LUNDBECK A/S (DK)	2015-08-04	—	—	US	disclosed
US-20150190395-A1	Novel Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors	H. LUNDBECK A/S (DK)	2015-07-09	—	—	US	disclosed
US-20150190395-A1	Novel Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors	H. LUNDBECK A/S (DK)	2015-07-09	—	—	US	disclosed
US-9018217-B2	Phenylimidazole derivatives as PDE10A enzyme inhibitors	H. LUNDBECK A/S (DK)	2015-04-28	—	—	US	disclosed
US-9018217-B2	Phenylimidazole derivatives as PDE10A enzyme inhibitors	H. LUNDBECK A/S (DK)	2015-04-28	—	—	US	disclosed
WO-2011072696-A1	2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS	H. LUNDBECK A/S (DK)	2011-06-23	—	—	WO	disclosed
WO-2011072694-A1	HETEROAROMATIC PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS	H. LUNDBECK A/S (DK)	2011-06-23	—	—	WO	disclosed
EP-2318394-A1	NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS	H. Lundbeck A/S (DK)	2011-05-11	—	—	EP	disclosed
US-20100016303-A1	NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS	H. LUNDBECK A/S (DK)	2010-01-21	—	—	US	disclosed
US-20100016303-A1	NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS	H. LUNDBECK A/S (DK)	2010-01-21	—	—	US	disclosed
US-20100016303-A1	NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS	H. LUNDBECK A/S (DK)	2010-01-21	—	—	US	disclosed
WO-2009152825-A1	NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS	H. LUNDBECK A/S (DK)	2009-12-23	—	—	WO	disclosed
WO-2009152825-A1	NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS	H. LUNDBECK A/S (DK)	2009-12-23	—	—	WO	disclosed
US-20080021069-A1	Receptor Function Regulating Agent	TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)	2008-01-24	—	—	US	disclosed
US-5371102-A	N,n-disubstituted thiocarbamide	UNIVERSITY OF HAWAII (US)	1994-12-06	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20100016303-A1	NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS	PDE10A, PDE5A, PDE3B	PSMB8 1782/4885RXFP1 3130/4885NPSR1 1701/4885
US-20080021069-A1	Receptor Function Regulating Agent	GPR119, INSR, GPR65	PSMB8 3592/4885RXFP1 126/4885NPSR1 103/4885
US-20170001983-A1	TRPA1 MODULATORS	TRPA1, TRPV1, TRPV2	PSMB8 2259/4885RXFP1 825/4885NPSR1 171/4885
US-20150190395-A1	Novel Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors	PDE10A, PDE5A, PDE3B	PSMB8 1782/4885RXFP1 3130/4885NPSR1 1701/4885
US-20150290191-A1	Heteroaromatic Phenylimidazole derivatives as PDE10A enzyme inhibitors	PDE10A, PDE3B, PDE12	PSMB8 1840/4885RXFP1 3829/4885NPSR1 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.